Video
Experts Discuss Common AEs With EGFR TKIs
Author(s):
Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.
Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects (AEs) with EGFR TKIs.
Zosia Piotrowska, MD, is a clinical researcher and lung cancer medical oncologist, Massachusetts General Hospital Cancer Center. Christine Lovly, MD, is an associate professor of medicine, Division of Hematology-Oncology, an Ingram associate professor of Cancer Research, co-leader, the Translational Research and Interventional Oncology Program, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center. Amanda Cass, PharmD, BCPS, is a clinical pharmacist, the Thoracic Oncology Clinic, Vanderbilt University Medical Center.
Lovly, Piotrowska, and Cass, explain that the inhibition of EGFR wild-type, which is commonly expressed in the skin, mucous membranes, and the gut, can lead to many of the skin toxicities associated with EGFR TKIs.
Moreover, the 3 experts discuss the adverse effects specifically associated with the use of osimertinib (Tagrisso). Osimertinib can lead to nail bed changes, rash, and sun sensitivity. Additionally, it is important to take up-front preventative measures to attempt to mitigate these skin toxicities.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
